Form 4 for NTLA Intellia Therapeutics, Inc.
Accepted 2025-12-12 00:00:00 ET · period of report 2025-12-11 · accession 0001193125-25-317551 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2025-12-12 | 2025-12-11+ | NTLA | LEONARD JOHN M | Pres, CEO, Dir | M - OptEx | $6.83 | +58.5K | 1.05M | +6% | +$399.7K |
| DMT | 2025-12-12 | 2025-12-11 | NTLA | LEONARD JOHN M | Pres, CEO, Dir | S - Sale+OE | $9.49 | -88.1K | 1.08M | -8% | -$836.4K |
| DMT | 2025-12-12 | 2025-12-11+ | NTLA | LEONARD JOHN M | Pres, CEO, Dir | M - OptEx | $0.00 | -58.5K | 8,557 | -87% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-11 | M | A | 49,959 | $6.83 | 1,127,074 | D | — | — | |
| 2 | Common | Common Stock | 2025-12-12 | M | A | 8,557 | $6.83 | 1,047,485 | D | — | — | |
| 3 | Common | Common Stock | 2025-12-11 | S | D | 5,355 | $9.59 | 1,038,928 | D | — | — | (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.57 to $9.65, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 11, 2025 at each separate price. |
| 4 | Common | Common Stock | 2025-12-11 | S | D | 32,832 | $9.47 | 1,044,283 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.30 to $9.57, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 11, 2025 at each separate price. |
| 5 | Common | Common Stock | 2025-12-11 | S | D | 49,959 | $9.49 | 1,077,115 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.33 to $9.64, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 11, 2025 at each separate price. |
| 6 | Derivative | Stock Option (right to buy) | 2025-12-12 | M | D | 8,557 | $0.00 | 0 | D | $6.83 · — to 2026-02-03 | 8,557 Common Stock | (F6) The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested in full as of December 11, 2025. |
| 7 | Derivative | Stock Option (right to buy) | 2025-12-11 | M | D | 49,959 | $0.00 | 8,557 | D | $6.83 · — to 2026-02-03 | 49,959 Common Stock | (F6) The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested in full as of December 11, 2025. |